- PR Newswire•13 days agoTapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today that its Board of Directors has approved a 1-for-12 reverse stock split of the Company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The Company believes that it will meet all of the listing requirements for listing the company's common stock on the NASDAQ Capital Market.
- PR Newswire•22 days ago
LOS ANGELES, Sept. 6, 2016 /PRNewswire/ -- SNN Incorporated, a global multimedia financial news and publishing company focused on the MicroCap stock market, and publisher of the MicroCap Review Magazine, ...
- PR Newswire•22 days agoTapImmune Issues Update: Multiple Phase 2 Trials, over $9 Million in New Funding & NASDAQ Uplisting Application
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update regarding significant recent financial, clinical and regulatory milestones achieved, as well as an outlook on future catalysts. Based on the strength of our cancer vaccine technology, we have established collaborations with some of the top medical, biopharmaceutical, and governmental organizations in the world. Also, the U.S. Food and Drug Administration (FDA) has granted TPIV 200 Fast Track designation and Orphan Drug status.
TapImmune, Inc. (TPIV)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||0.10|
|Avg Vol (3m)||194,262|
|Dividend & Yield||N/A (N/A)|